- Novavax Inc NVAX has initiated a pediatric expansion of its Phase 3 PREVENT-19 trial for NVX-CoV2373, its COVID-19 vaccine candidate.
- The additional arm of the ongoing PREVENT-19 pivotal trial will evaluate the efficacy, safety, and immunogenicity of NVX-CoV2373 in up to 3,000 adolescents aged 12-17.
- Participants will randomly receive either the vaccine candidate or placebo in two doses, administered 21 days apart.
- A blinded crossover is planned to occur six months after the initial set of vaccinations to ensure that all trial participants receive the active vaccine.
- Participants will be monitored for safety for up to two years following the final dose.
- Price Action: NVAX shares are down 6.3% at $222 on the last check Monday.
NVAXNovavax Inc
$8.150.62%
Edge Rankings
Momentum77.96
Growth86.14
Quality-
Value26.81
Price Trend
Short
Medium
Long
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
